

-11-

REMARKS

Allowable Subject Matter

Applicant acknowledges with appreciation the examiner's allowance of claims 1-3 and 8-45. Applicant further acknowledges with appreciation the examiner's determination that claim 51 is allowable.

Amendment to Claims 6 47 and 48

Basis for the amendments to claims 6, 47 and 48 can be found throughout the specification including, for example, in original claims 1, 6, 47 and 48. No new matter has been added with the amendment.

Rejection under 35 U.S.C. 112, Second Paragraph

Claims 6 and 7 have been rejected under 35 U.S.C. 112, second paragraph, as being indefinite because claim 6 omits the formula represented as formula (I).

Claim 6 has been amended to recite the formula represented as formula (I), thereby obviating this rejection of claims 6 and 7.

Rejections under 35 U.S.C. 102(b)

Claims 6, 47-49 have been rejected under 35 U.S.C. 102(b) as being anticipated by Fu *et al.* (*Gaodeng Xuexiao Huaxue Xuebao*, 18(7):1071-1079 (1997) (Abstract only).

Claims 6 and 47-50 have been rejected under 35 U.S.C. 102(b) as being anticipated by Cherif *et al.* (*Bioorganic Med. Chem. Lett.*, 12(9):1237-1240 (2002) (Abstract only)).

Claim 6 has been amended to remove the masked aldehyde group $-\text{CH}_2\text{OH}$.

Claim 47 has been amended to remove the masked aldehyde group $-\text{CH}_2\text{OH}$.

Claim 48 has been amended to remove the masked aldehyde groups $-\text{CH}_2\text{OH}$.

Neither Fu *et al.* nor Cherif *et al.* disclose the subject matter of claims 6 and 47-

-12-

50 as amended. As such, Fu *et al.* and Cherif *et al.* do not anticipate claims 6 and 47-50 as amended.

Respectfully submitted,

NOVARTIS VACCINES AND DIAGNOSTICS, INC.

Dated: **November 7, 2009** By: **/Helen Lee/**.
Helen Lee
Reg. No. 39,270

Customer No. 27476
NOVARTIS VACCINES AND DIAGNOSTICS, INC.
Telephone: (510) 923-2192
Facsimile: (510) 655-3542